# Edgar Filing: APPLIED DNA SCIENCES INC - Form NT 10-Q

## APPLIED DNA SCIENCES INC Form NT 10-Q February 15, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

Commission File Number: 002-78682

NOTIFICATION OF LATE FILING
_  Form 10-K  _  Form 20-F  _  Form 11-K  X  Form 10-Q  _  Form 10-D  _  Form N-SAR
For Period Ended: December 31, 2006
_  Transition Report on Form 10-K  _  Transition Report on Form 20-F  _  Transition Report on Form 11-k  _  Transition Report on Form 10-Q  _  Transition Report on Form N-SAR
For the Transition Period Ended:
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Applied DNA Sciences, Inc.
Full name of registrant
Former name if applicable
25 Health Sciences Drive, Suite 113
Address of principal executive office
Stony Brook, New York 11790
City, state and zip code

### Edgar Filing: APPLIED DNA SCIENCES INC - Form NT 10-Q

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- $\mid$  (a) The reasons described in reasonable detail in Part III of this form  $\mid$  could not be eliminated without unreasonable effort or expense;
- | (b) The subject annual report, semi-annual report, transition report on | Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion | thereof, will be filed on or before the fifteenth calendar day following [X] | the prescribed due date; or the subject quarterly report or transition | report on Form 10-Q or subject distribution report on Form 10-D, or | portion thereof, will be filed on or before the fifth calendar day | following the prescribed due date; and
  - $\mid$  (c) The accountant's statement or other exhibit required by Rule 12b-25(c)  $\mid$  has been attached if applicable.

#### PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report, or portion thereof, could not be filed within the prescribed time period.

Applied DNA Sciences, Inc. (the "Company") is filing this Notification of Late Filing on Form 12b-25 with respect to the Company's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2006 (the "Form 10-QSB"). The Company is unable, without unreasonable effort and expense, to file the Form 10-QSB on a timely basis due to unforeseen delays in the collection and review of information and the completion of drafting the necessary responses to items required to be included in the Form 10-QSB.

The Company expects that the Form 10-QSB will be filed no later than February 20, 2007.

#### PART IV -OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

James A. Hayward	(631)	444-6862
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

|X| Yes |\_| No

### Edgar Filing: APPLIED DNA SCIENCES INC - Form NT 10-Q

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Applied DNA Sciences, Inc.
----(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: February 15, 2007 By: /s/ JAMES A. HAYWARD

\_\_\_\_\_

James A. Hayward Chief Executive Officer